INFOGRAPHIC: The rise of the pharmacogenomic biomarker in clinical trials
This article was originally published in Scrip
Executive Summary
Since 2002, there has been a steady increase in the number of oncology clinical trials identifying, testing or using pharmacogenomic (PGX) biomarkers to either select or stratify patients, new research by Citeline has confirmed.